文献速递中毒与环境急症消化、代谢与肾脏急症

氟美吡唑作为高危对乙酰氨基酚过量辅助治疗的临床影响

Clinical impact of fomepizole as an adjunct therapy in high-risk acetaminophen overdose.
PubMed 文献 · Am J Emerg Med · 2026-03-17
一句话结论回顾性队列研究显示,高危对乙酰氨基酚过量患者在接受N-乙酰半胱氨酸基础上加用氟美吡唑,未改善临床结局,不支持常规使用。

该回顾性队列研究纳入2018年1月至2022年12月向美国四个中毒控制中心报告的391例高危对乙酰氨基酚过量患者,定义为摄入后4小时或以上血清浓度≥300 μg/mL,或入院时对乙酰氨基酚浓度(mcg/mL)乘以天冬氨酸氨基转移酶(U/L)或丙氨酸氨基转移酶(U/L)的乘积≥10,000,且接受N-乙酰半胱氨酸治疗。比较加用氟美吡唑与单用N-乙酰半胱氨酸患者的临床特征和结局,采用逻辑回归分析。结果显示两组在国家中毒数据系统结局严重程度、ICU住院时间或N-乙酰半胱氨酸疗程方面无显著差异;氟美吡唑亚组分析中,无论在N-乙酰半胱氨酸启动后24小时内或之后给药,结局也相似。作者认为,氟美吡唑作为高危对乙酰氨基酚过量的辅助治疗未改善临床结局,虽未报告不良反应,但本研究不支持常规使用。

要点

  • 高危对乙酰氨基酚过量定义为摄入后4小时或以上血清浓度≥300 μg/mL,或入院时对乙酰氨基酚浓度(mcg/mL)乘以AST或ALT(U/L)的乘积≥10,000。
  • 391例接受N-乙酰半胱氨酸治疗的高危患者中,加用氟美吡唑组与未加用组在国家中毒数据系统结局严重程度、ICU住院时间或N-乙酰半胱氨酸疗程方面无显著差异。
  • 氟美吡唑亚组分析中,在N-乙酰半胱氨酸启动后24小时内或之后给药,结局相似。
  • 未报告氟美吡唑相关不良反应,但本研究不支持在该人群中常规使用氟美吡唑作为辅助治疗。

适用人群与场景

  • 纳入标准:2018年1月至2022年12月向美国四个中毒控制中心报告的高危对乙酰氨基酚摄入患者,定义为摄入后4小时或以上血清浓度≥300 μg/mL,或入院时对乙酰氨基酚浓度(mcg/mL)乘以AST(U/L)或ALT(U/L)的乘积≥10,000,且接受N-乙酰半胱氨酸治疗。
  • 排除标准:有既往肝病病史记录、病例资料不足、或同时摄入有毒醇或其他肝毒性物质。

诊断标准与关键阈值

  • 高危对乙酰氨基酚过量:摄入后4小时或以上血清浓度≥300 μg/mL,或入院时对乙酰氨基酚浓度(mcg/mL)乘以AST(U/L)或ALT(U/L)的乘积≥10,000。

研究设计与关键结果

  • 研究类型:回顾性队列研究,纳入391例患者,来自美国四个中毒控制中心,时间为2018年1月至2022年12月。
  • 干预与对照:加用氟美吡唑作为N-乙酰半胱氨酸辅助治疗 vs 单用N-乙酰半胱氨酸。
  • 主要结果:两组在国家中毒数据系统结局严重程度、ICU住院时间或N-乙酰半胱氨酸疗程方面无显著差异。
  • 亚组分析:氟美吡唑在N-乙酰半胱氨酸启动后24小时内或之后给药,结局相似。
  • 不良事件:未报告氟美吡唑相关不良反应。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,氟美吡唑作为高危对乙酰氨基酚过量的辅助治疗未改善临床结局,本研究不支持在该人群中常规使用氟美吡唑。
  • 未报告氟美吡唑相关不良反应。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: The objectives of this study were to characterize and compare clinical outcomes in patients with high-risk acetaminophen overdose who received fomepizole as an adjunct to N-acetylcysteine treatment to those who received N-acetylcysteine only.

MATERIAL AND METHODS: This was a retrospective cohort study of patients reported to four United States poison control centers between January 2018 and December 2022. Patients with high-risk acetaminophen ingestion-defined as a serum concentration ≥ 300 μg/mL at 4 h or more post-ingestion, or a multiplication product (acetaminophen concentration in mcg/mL multiplied by either aspartate aminotransferase in units per liter or alanine aminotransferase in units per liter) ≥10,000-upon admission who received N-acetylcysteine were included. Exclusion criteria included documented history of pre-existing liver disease, insufficient case details, or co-ingestion of either a toxic alcohol or another hepatotoxic substance. Clinical characteristics and outcomes were compared using logistic regressions between patients who received fomepizole as an adjunct to N-acetylcysteine treatment to those who received N-acetylcysteine only. A subgroup analysis assessed the impact of fomepizole timing (≤24 h versus >24 h) after N-acetylcysteine initiation.

RESULTS: Among the 391 patients included, there were no significant differences in National Poison Data System outcome severity, intensive care unit stay, or N-acetylcysteine duration between patients who received fomepizole and those who did not. In the subgroup analysis of fomepizole recipients, outcomes were also similar regardless of whether fomepizole was administered within or after 24 h of N-acetylcysteine initiation.

DISCUSSION: Fomepizole as an adjunct to N-acetylcysteine in patients with high-risk acetaminophen overdose did not improve clinical outcomes. Although no adverse effects to fomepizole were reported, routine use in this setting remains unsupported by this study.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Gartner HT, Simmons RE, Stott M, et al. Clinical impact of fomepizole as an adjunct therapy in high-risk acetaminophen overdose. Am J Emerg Med. 2026. PMID: 41886998. doi:10.1016/j.ajem.2026.03.014

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。